▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #60 by analyst upside · 2026-09-27
VVOS
Vivos Therapeutics, Inc.
Healthcare · Market Cap $3M · P/E 0x
ANALYST PRICE TARGET
+1404.4%
implied upside to consensus target
Current Price $0.14
Consensus Target $2.12
Bull Target $3.1
Bear Target $0.75
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
1
Sell
0
52-Week Low $0.14
52-Week High $3.45
YTD Return -94.4%
FUNDAMENTALS
Market Cap $3M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $21M
Profit Margin -121.8%
52-WEEK RANGE
52-Week Low $0.14
52-Week High $3.45
Current Price $0.14
Bear Target $0.75
Bull Target $3.1
● Now $0.14 ● Target $2.12
TRADING DATA
Avg Volume 11.8M
YTD Return -94.4%
Analyst Count 3
Consensus Buy
Upside to Target +1404.4%
Last Updated 2026-09-27

ANALYST SUMMARY

Vivos Therapeutics, Inc. (VVOS) is currently trading at $0.14 with a Wall Street consensus price target of $2.12, implying potential upside of 1404.4% over the next 12 months. 3 analysts currently cover VVOS, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $3.1, while the most cautious has a target of $0.75.

VVOS operates in the Healthcare sector with a market capitalisation of $3M. The stock is down 94.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.14 – $3.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VVOS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital - Reiterated
Buy → Buy 2026-06-04 Building track record
Ascendiant Capital - Reiterated
Buy → Buy 2026-04-22 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-17 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2025-12-03 Building track record
HC Wainwright & Co. ● Initiated
Buy 2025-11-17 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2025-09-09 Building track record
Ascendiant Capital - Reiterated
Buy → Buy 2025-04-15 Building track record
Ascendiant Capital reit
Buy → Buy 2024-11-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →